Best Practices for the Implementation of Clinical Advances in HR-Positive/HER2-Negative Breast Cancer

Download these slides from an expert-led symposium reviewing updates in oral targeted therapy for HR-positive/HER2-negative breast cancer and implementation in clinical practice.
Allison Butts, PharmD, BCOP
Kristina F. Byers, PharmD, BCOP
Format: Microsoft PowerPoint (.ppt)
File Size: 988 KB
Released: March 30, 2022

Acknowledgements

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

Related Content

Downloadable clinical resource with practical guidance on how to talk with your transgender patients about gender identity, including related terminology, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 30, 2022

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: June 28, 2022

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings